
Jonathan Lopez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8985047/publications.pdf Version: 2024-02-01



IONATHAN LODEZ

#	Article	IF	CITATIONS
1	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 2022, 14, 599.	3.7	8
2	Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. Annals of Intensive Care, 2022, 12, 21.	4.6	10
3	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. European Journal of Cancer, 2022, 166, 87-99.	2.8	21
4	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers, 2022, 14, 98.	3.7	16
5	Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer. Nature Communications, 2022, 13, 1985.	12.8	14
6	Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with <i>RAS</i> or <i>BRAF</i> K601E mutations?. Cytopathology, 2021, 32, 37-44.	0.7	4
7	Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. Journal of Experimental Medicine, 2021, 218, .	8.5	85
8	Acral lentiginous melanoma with HER2/ErbB2 amplification. European Journal of Dermatology, 2021, 31, 588-590.	0.6	0
9	Feasibility and performance of the Idyllaâ"¢ NRAS / BRAF cartridge mutation assay on thyroid liquidâ€based fineâ€needle aspiration. Diagnostic Cytopathology, 2021, 49, 1265-1271.	1.0	3
10	Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma. Biomedicines, 2021, 9, 1474.	3.2	4
11	Concomitant <i>GNA11</i> and <i>SF3B1</i> mutations in two cases of melanoma associated with blue naevus. Clinical and Experimental Dermatology, 2020, 45, 123-126.	1.3	1
12	Dermoscopic features in <i><scp>BRAF</scp></i> and <i><scp>NRAS</scp></i> primary cutaneous melanoma: association with peppering and blueâ€white veil. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e57-e59.	2.4	5
13	Towards standardization of immune functional assays. Clinical Immunology, 2020, 210, 108312.	3.2	8
14	Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives. Cancers, 2020, 12, 2414.	3.7	10
15	Transcriptomic and immunohistochemical approaches identify HLA-G as a predictive biomarker of gestational choriocarcinoma resistance to monochemotherapy. Gynecologic Oncology, 2020, 158, 785-793.	1.4	9
16	The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production. Oncogene, 2020, 39, 3056-3074.	5.9	39
17	Preoperative Role of <i>RAS</i> or <i>BRAF</i> K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules. World Journal of Surgery, 2020, 44, 2264-2271.	1.6	10
18	Poorly differentiated thyroid carcinoma with pleomorphic giant cells—a case report. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 597-601.	2.8	2

JONATHAN LOPEZ

#	Article	IF	CITATIONS
19	Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression. Gynecologic Oncology, 2020, 157, 775-782.	1.4	2
20	COPA Syndrome as a Cause of Lupus Nephritis. Kidney International Reports, 2019, 4, 1187-1189.	0.8	19
21	Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies. European Journal of Cancer, 2019, 120, 40-46.	2.8	19
22	mTORC1 Activation Requires DRAM-1 by Facilitating Lysosomal Amino Acid Efflux. Molecular Cell, 2019, 76, 163-176.e8.	9.7	37
23	TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. European Journal of Cancer, 2019, 108, 41-49.	2.8	46
24	Application of Mito-Priming to Generate BCL-2 Addicted Cells. Methods in Molecular Biology, 2019, 1877, 45-60.	0.9	1
25	Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies. Cytokine, 2019, 113, 446-452.	3.2	51
26	The dynamic molecular landscape of malignant melanomas arising from congenital or common nevi. Integrative Molecular Medicine, 2019, 6, .	0.3	1
27	Predictive factors of outcome in poorly differentiated thyroid carcinomas. European Journal of Cancer, 2018, 92, 40-47.	2.8	51
28	Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10. Cancer Research, 2018, 78, 1404-1417.	0.9	34
29	Mitochondrial inner membrane permeabilisation enables mt <scp>DNA</scp> release during apoptosis. EMBO Journal, 2018, 37, .	7.8	313
30	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. International Journal of Molecular Sciences, 2018, 19, 1251.	4.1	11
31	Reply to Dr Ozden et al Cytopathology, 2018, 29, 599-599.	0.7	0
32	Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer. Thyroid, 2018, 28, 1174-1179.	4.5	20
33	BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications, 2017, 8, 1123.	12.8	43
34	Molecular testing of <i>BRAF, RAS</i> and <i>TERT</i> on thyroid FNAs with indeterminate cytology improves diagnostic accuracy. Cytopathology, 2017, 28, 482-487.	0.7	49
35	Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. British Journal of Cancer, 2017, 117, 583-587.	6.4	70
36	Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspaseÂdeficiency. Nature Cell Biology, 2017, 19, 1116-1129.	10.3	181

JONATHAN LOPEZ

#	Article	IF	CITATIONS
37	Mito-priming as a method to engineer Bcl-2 addiction. Nature Communications, 2016, 7, 10538.	12.8	53
38	Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study. Targeted Oncology, 2016, 11, 71-82.	3.6	7
39	TIF1 $\hat{1}^3$ interferes with TGF $\hat{1}^2$ 1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. BMC Cancer, 2015, 15, 453.	2.6	28
40	Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death. Molecular Cell, 2015, 57, 860-872.	9.7	341
41	Mitochondrial apoptosis: killing cancer using the enemy within. British Journal of Cancer, 2015, 112, 957-962.	6.4	581
42	Killing the Killer: PARC/CUL9 Promotes Cell Survival by Destroying Cytochrome c. Science Signaling, 2014, 7, pe17.	3.6	7
43	Bcl-wav and the mitochondrial calcium uniporter drive gastrula morphogenesis in zebrafish. Nature Communications, 2013, 4, 2330.	12.8	64
44	Tif1Î ³ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (Cambridge), 2013, 140, 167-175.	2.5	24
45	Data-Driven Modeling of Src Control on the Mitochondrial Pathway of Apoptosis: Implication for Anticancer Therapy Optimization. PLoS Computational Biology, 2013, 9, e1003011.	3.2	8
46	Amniotic fluid glial fibrillary acidic protein (AFâ€GFAP), a biomarker of open neural tube defects. Prenatal Diagnosis, 2013, 33, 990-995.	2.3	8
47	Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik. Cell Death and Differentiation, 2012, 19, 1459-1469.	11.2	43
48	Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cells. EMBO Reports, 2011, 12, 665-672.	4.5	57
49	New approach for measurement of non-SHBG-bound testosterone in human plasma. Analytica Chimica Acta, 2010, 658, 87-90.	5.4	14
50	Active Fragments from Pro- and Antiapoptotic BCL-2 Proteins Have Distinct Membrane Behavior Reflecting Their Functional Divergence. PLoS ONE, 2010, 5, e9066.	2.5	26
51	Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases. Oncogene, 2009, 28, 3246-3260.	5.9	8